Gilead Sciences, Inc. vs Mattel Inc — how do they compare? Gilead Sciences, Inc. trades at $135.47 (market cap $168.35B), while Mattel Inc trades at $15.03 (market cap $4.30B). The key difference: Gilead Sciences, Inc. is far larger — about 39.2× Mattel Inc's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Mattel Inc pays none. Which is the better fit depends on your goals.
| GILD | MAT | |
|---|---|---|
Market Cap | $168.35B | $4.30B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $22.16 |
52-Week Low | $110.56 | $13.05 |
Enterprise Value | $191.42B | $6.52B |
Dividend Yield | 2.42% | — |
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →